With that backdrop, let's consider two healthcare dividend stocks for investors focused on the long game: Merck ( MRK -0.44%) and Medtronic ( MDT -0.15%).

Embecta said Tuesday that it will cancel its insulin patch pump program just months after receiving clearance from the Food and Drug Administration for its first product. The Parsippany, New ...

Provided image of Medtronic's Smart MDI system combines its InPen smart insulin pen with continuous glucose monitor to help users calculate insulin doses.

Medtronic also said the app will be the ... data earlier this week on meal detection technology from its MiniMed 780G insulin pump. Presented at the Asian Conference on Innovative Therapies ...

R3 Vascular announced today that the FDA granted investigational device exemption (IDE) to evaluate its Magnitude drug-eluting bioresorbable scaffold. Mountain View, California-based R3 Vascular ...

Medtronic has also initiated a voluntary field action for its MiniMed™ 600 and 700 series insulin pumps due to potential battery issues. These are all recent developments in Medtronic's journey.

Delivering on commitments, executing ahead of expectations, and raising guidanceInnovation driving sustained growth across many franchises: TAVR, PFA, Leadless Pacemakers, Diabetes, Spine ...

Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any of the information contained in this press release ...

Medtronic (NYSE:MDT ... along with a strategic insulin pump partnership with Abbott, are setting the stage for future gains. CEO Geoff Martha pointed to their high-impact pipeline as a driver ...